Romidepsin is a histone deacetylase inhibitor (HDACi) approved by the FDA for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. It has shown promising activity in preclinical studies and early clinical trials, particularly in advanced stages of CTCL. Romidepsin works by inhibiting histone deacetylase enzymes, leading to increased histone acetylation, which affects gene expression and promotes apoptosis in cancer cells. It is well-tolerated and has a favorable safety profile. Romidepsin demonstrated significant clinical activity in patients with CTCL, with a 34% overall response rate in a Phase II trial. It was effective in both mycosis fungoides (MF) and Sézary syndrome (SS), with some patients achieving complete remission. The drug was well-tolerated, with common adverse effects including fatigue, nausea, and thrombocytopenia. Cardiac toxicity was observed in some patients, but it was generally manageable. Romidepsin's mechanism of action involves cell cycle arrest and apoptosis, and it has shown activity against various T-cell lymphomas. It is a substrate for P-glycoprotein, which may affect its distribution and efficacy in certain tumor cells. The drug's pharmacokinetics show rapid elimination from the bloodstream, with a short half-life, and it is extensively metabolized by the cytochrome P450 system. Despite its efficacy, there are unanswered questions regarding the exact mechanism of action of romidepsin in CTCL and its potential for combination therapies. Further research is needed to better understand its role in CTCL and to explore its use in combination with other treatments. Comparative studies with other HDAC inhibitors, such as vorinostat, are also needed to determine the most effective treatment options for patients with CTCL. Overall, romidepsin has shown significant clinical activity in the treatment of CTCL, with good durability and tolerable side effects.Romidepsin is a histone deacetylase inhibitor (HDACi) approved by the FDA for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. It has shown promising activity in preclinical studies and early clinical trials, particularly in advanced stages of CTCL. Romidepsin works by inhibiting histone deacetylase enzymes, leading to increased histone acetylation, which affects gene expression and promotes apoptosis in cancer cells. It is well-tolerated and has a favorable safety profile. Romidepsin demonstrated significant clinical activity in patients with CTCL, with a 34% overall response rate in a Phase II trial. It was effective in both mycosis fungoides (MF) and Sézary syndrome (SS), with some patients achieving complete remission. The drug was well-tolerated, with common adverse effects including fatigue, nausea, and thrombocytopenia. Cardiac toxicity was observed in some patients, but it was generally manageable. Romidepsin's mechanism of action involves cell cycle arrest and apoptosis, and it has shown activity against various T-cell lymphomas. It is a substrate for P-glycoprotein, which may affect its distribution and efficacy in certain tumor cells. The drug's pharmacokinetics show rapid elimination from the bloodstream, with a short half-life, and it is extensively metabolized by the cytochrome P450 system. Despite its efficacy, there are unanswered questions regarding the exact mechanism of action of romidepsin in CTCL and its potential for combination therapies. Further research is needed to better understand its role in CTCL and to explore its use in combination with other treatments. Comparative studies with other HDAC inhibitors, such as vorinostat, are also needed to determine the most effective treatment options for patients with CTCL. Overall, romidepsin has shown significant clinical activity in the treatment of CTCL, with good durability and tolerable side effects.